Navigating the Complex Treatment Landscape of Multiple Myeloma in Transplant Eligible Patients

Unmet Needs and the Future of Myeloma
February 03, 2020 – 
The panelist shares his thoughts on unmet needs and the future of therapy in the management of multiple myeloma.
Maintenance Therapy and Relapse/Refractory Treatment
February 03, 2020 – 
An expert provides an understanding of de-escalation or maintenance therapy and shares treatment plans for relapsed/refractory multiple myeloma.
MRD Assessment and Prognostic Factors for Myeloma
January 20, 2020 – 
Dr Chari reviews the MRD assessment and how he uses it in his practice.
Studies With a PI-Based Quadruplet Regimen and Sequencing
January 20, 2020 – 
The panelist describes the PI-based quadruplet regimen studies. He also discusses the practical sequencing of investigational treatment strategies with the current standard of care.
Treatment of Newly Diagnosed Symptomatic Myeloma and Dosing Regimens
January 17, 2020 – 
The expert reviews the standard for treatment of newly diagnosed symptomatic myeloma. He also reviews the different dosing regimens used.
Proteasome Inhibitor-Based Treatment Regimens
January 17, 2020 – 
Dr Chari discusses the use of proteasome inhibitors [PIs] in the treatment of multiple myeloma and the differences among the available agents.
Transplant Eligibility, NCCN Recommendations, and Sequencing
December 19, 2019 – 
Dr Ajai Chari defines when a patient is transplant eligible and what proportion of patients often are. He reviews the NCCN Guidelines and the standard sequencing of MM in transplant-eligible patients.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.